CROHN'S RESEARCH SPOTLIGHT
Propel a Cure is pleased to be featuring these international Crohn's disease research teams.
DR. JOANA TORRES
Hospital Beatriz Ângelo (Loures, Portugal)
Hospital da Luz (Lisbon)
​
A leading scientist in IBD prediction and prevention, Dr. Joana Torres is based at Hospital Beatriz Ângelo (Loures, Portugal), and Hospital da Luz (Lisbon) as a Consultant in Gastroenterology, where she oversees the IBD clinic, actively combining clinical practice with research and teaching. Her research focuses on populations at risk for IBD and newly diagnosed IBD, with the aim of finding predictors of IBD development and disease course. She is involved in several large projects in this sphere, including the potential development of preventive interventions, such as the PREDICT study, the EARLY-CD study, the GlycanTrigger project, and the large European Union-funded INTERCEPT study.
Dr. Torres completed her fellowship in Gastroenterology at Coimbra, Portugal. After post-doctoral training at the Icahn School of Medicine at Mount Sinai, New York, she completed her PhD, and was appointed an Auxiliary Professor at the University of Lisbon.
She has served in the European Crohn and Colitis Organisation (ECCO) as a member and chair of the Guideline Committee (GuiCom). She is also currently a member of the Gastroenterology Portuguese Society Board and the United European Gastroenterology (UEG) Public Affairs Committee. In addition, Dr. Torres is Associate Editor for Clinical Gastroenterology & Hepatology. Among her many awards are the ECCO Travel Award, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Travel Award, and the National Gastroenterology Award. Dr. Torres received the UEG Rising Star Award in 2023 for her work in preclinical IBD.
DR. KATERINA CHATZI & DR. JASPER E. NEGGERS
PROMAKHOS THERAPEUTICS
​
Propel a Cure is pleased to support Promakhos Therapeutics’s current study, "Validating the Role of Mucosal Innate Immune Deficiency in Crohn’s Disease."
Dr. Katerina Chatzi is a co-founder and the Chief Executive Officer and President of Promakhos Therapeutics. She is a distinguished scientist-entrepreneur with expertise in immunology, protein secretion, biochemistry, bacteriology, cell biology and business development. She has performed biomedical research for over 15 years across four different countries, uncovering fundamental principles underlying bacterial secretion, protein folding, antibiotic resistance, and cell cycle regulation. She earned her PhD at the University of Crete, where she was awarded the prestigious Heraclitus II fellowship from the National Strategic Innovation Program. In Europe, she also performed research at Uppsala University in Sweden and the KU Leuven in Belgium.
Dr. Chatzi arrived in the United States to work as a postdoctoral researcher at Harvard. While there, she engaged in various research-related business development programs across the Harvard and Massachusetts ecosystems. Her combined scientific, clinical, and business experience led her to assemble a team and found Promakhos Therapeutics in the quest to help patients through developing novel immunomodulatory therapeutics.
​
Dr. Jasper E. Neggers is a co-founder, Chief Scientific Officer, and Secretary of Promakhos Therapeutics. He hails from the Netherlands and completed his PhD at the Rega Institute for Medical Research at the KU Leuven, Belgium. With a background in microbiology, immunology, cell biology, target identification and validation, drug discovery, and functional genomics, he was among the first scientists to apply CRISPR/Cas to genetically engineer human cells. Dr. Neggers arrived in the United States as a postdoctoral fellow at the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard to spearhead a team of researchers to identify and validate new therapeutic targets for cancer. He quickly distinguished himself and was awarded a Damon Runyon Cancer Research Foundation fellowship. His work has nominated several new high-priority therapeutic targets for cancer and has led to the initiation of new drug discovery campaigns. As a rising scientific leader, Dr. Neggers was on his way to becoming an assistant professor after receiving the National Cancer Institute Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers. However, ultimately, Dr. Neggers decided to pivot to translational research to maximize patient impact. As a result, he elected to return a recently awarded million-dollar grant to join Dr. Katerina Chatzi to co-found Promakhos Therapeutics.
DR. PRADIPTA GHOSH
UNIVERSITY OF CALIFORNIA, SAN DIEGO
​
Propel a Cure is excited to support a project led by Dr. Pradipta Ghosh titled, “Modulation of Dysfunctional Sensing and Signaling in Crohn’s Disease”. Dr Ghosh is a clinician scientist and professor in the Department of Medicine and Cellular and Molecular Medicine at the University of California, San Diego. She is also the Director of the Institute for Network Medicine as well as the Executive Director and Co-founder of the HUMANOID Center of Research Excellence.
Dr. Ghosh is inspired by transdisciplinary ideas and seeks to understand the fundamental rules of biological communication and networking with the goal “to design drugs that can fix the broken machines in diverse diseases.” Most systems, such as our bodies or our cells, appear diverse, complex, and heterogeneous. However, there are fundamental unifying principles operating and abiding by the same laws of nature. Combining novel mathematical tools, computational algorithms and multi-omic approaches to view networks inside cells, Dr. Ghosh and colleagues have been able to identify disease patterns, high-value biomarkers and drug targets for diseases that have no cure.
Any tissue with stem cells can be grown as an organoid. HUMANOID™’s approach allows researchers to isolate, expand, and biobank 3D organoids from healthy and diseased human tissues to study organ physiology and human disease; microbes, immune cells, or non-immune support cells can also be incorporated into a model. This technology is also being introduced into clinical trials as part of a “Phase 0”, which can help gauge the efficacy and toxicity of potential drugs before testing them on human patients. HUMANOID™’s organoids can also replicate critical aspects of human disease and facilitate personalized medicine by testing existing drugs or multi-drug cocktails to help individual patients.
DR. BEN WOOLSTON
WOOLSTON LAB, NORTHEASTERN UNIVERSITY, BOSTON
Propel a Cure, in partnership with the Mendez Family Foundation, is proud to fund a project being spearheaded by Dr. Ben Woolston, head of the Woolston Lab at Northeastern University (NEU): “Defining the Role of Microbial Hydrogen Sulfide in Intestinal Inflammation”.
Dr. Woolston has harnessed his training in metabolic engineering, synthetic biology, biochemistry, and microbiology to engineer microbes as diagnostics and therapeutics in the human gut microbiota in work sponsored by the DOE and NIH. Applications of these engineered microbes in gut-on-a-chIp models may give better insight into disease pathways, the impact of specific metabolites on the gut ecosystem, and a better mechanistic understanding of bacteria-host interactions for IBD and other diseases.
Dr. Woolston’s expertise also extends to biofuel and biochemical production. His work has been recognized through a range of awards, including the 2020 International Metabolic Engineering Society Jay Bailey Young Investigator Award, the 2021 Biotechnology and Bioengineering Daniel IC Wang Young Investigator Award, and more recently an NIH NIBIB Trailblazer Award in 2022.
Dr. Woolston joined the NEU Chemical Engineering Department as an Assistant Professor in January 2020, where he has taught biochemical engineering and a graduate course in kinetics and reactor design. As a National Science Foundation Research Fellow, he received his PhD in Chemical Engineering in 2017 from MIT under the guidance of Professor Greg Stephanopoulos, where his research focused on the development of genetic tools to enable metabolic engineering in anaerobic carbon dioxide-fixing microbes.
His post-doctoral work was conducted in the laboratory of Professor Emily Balskus in the Chemistry & Chemical Biology Department at Harvard University, where he studied microbial metabolic pathways and enzymes that contribute to the health and stability of health-associated Lactobacilli in the human vaginal microbiota.
​
​
JUSTIN HAYES
WOOLSTON LAB, NORTHEASTERN UNIVERSITY, BOSTON
Justin joined the Northeastern University Chemical Engineering Department as a National Science Foundation Research Fellow in 2020. Currently, he is completing his PhD under Dr. Benjamin Woolston and Dr. Ryan Koppes. His research is focused on leveraging synthetic biology and organ-on-chip technology to probe human-microbome interactions. He recently spun out a microbial therapeutics company from his PhD work – Concordance Therapeutics – which is focused on developing microbial therapeutics for intestinal diseases with high unmet need such as inflammatory bowel disease.
​
​
DR. JAMES LEE
THE FRANCIS CRICK INSTITUTE, LONDON
Dr. James Lee, a clinician-scientist with clinical expertise in IBD, seeks to better understand the biology of immune-mediated disease, and translate that knowledge for patient benefit. He completed medical training at the University of Oxford (2004) and his PhD at the University of Cambridge. He received clinical training in gastroenterology as a clinical lecturer (University of
Cambridge), before being awarded a Wellcome Trust Intermediate Clinical Fellowship in 2015. Dr. Lee spent 2 years of this award at Harvard University before returning to the University of Cambridge in 2018 to establish a research group at the newly-opened Cambridge Institute for Therapeutic Immunology and Infectious Disease. He joined the Francis Crick Institute in London as a Clinician Scientist Group Leader in 2021.
Dr. Lee has published over 50 research papers, including first/senior author papers in Cell, Nature Genetics, Journal of Clinical Investigation, Gut and EMBO Molecular Medicine, and co-authored papers in journals including Nature, Cell, Nature Immunology and Journal of Experimental Medicine. His work has provided insights into why patients with the same disease often experience different outcomes, including the discovery of a genetic contribution to prognosis that is distinct from the contribution to disease susceptibility. With his group, he has also developed approaches to leveraging genetic associations, leading to discoveries into disease mechanisms. In the summer of 2024, a study from a team he led garnered international headlines for uncovering the role of the ETS2 genetic pathway in IBD and other inflammatory diseases.​​
DR. JEAN-FRÉDÉRIC COLOMBEL
MOUNT SINAI HOSPITAL, NEW YORK CITY
​
Dr. Jean-Frédéric Colombel is an internationally renowned inflammatory bowel disease (IBD) clinician and researcher. He is widely recognized as one of the most effective collaborators in the field, regularly bringing together geneticists, microbiologists, epidemiologists, systems engineers, and IBD clinicians to study new concepts in the causes, prognosis, diagnosis, and treatment of IBD.
​
Dr. Colombel is the Director of the Leona M. and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease Center and the Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai in New York. He conducts research and cares for patients at the Icahn School of Medicine, where he is a Professor of Medicine. In 2018, he was awarded the prestigious Sherman Prize, the first recipient to have trained and practiced outside the U.S.
Prior to arriving in New York in 2013, Dr. Colombel was the Head of the Department of Hepatogastroenterology at CHU de Lille, France. While in Lille, Dr. Colombel conducted research that led to seminal discoveries in IBD, including ASCA as a seromarker for Crohn’s disease; the first gene for IBD – NOD2 – which remains the most important genetic risk factor for Crohn’s disease; and a new strain of E. coli (adherent invasive E. coli, or AIEC) that is associated with ileal Crohn’s disease.​​
DR. SAMUEL FORSTER
HUDSON INSTITUTE - MELBOURNE, AUSTRALIA
Dr. Samuel Forster is one of the world’s leading microbiome scientists and has pioneered key research in metagenomics and anaerobic culturing of bacteria. A CSL Centenary Fellow and Associate Professor at the Hudson Institute of Medical Research in Melbourne, Australia, he received his highly prestigious fellowship to advance his work using the bacteria of the human microbiome to treat inflammatory bowel disease (IBD).
He is also the Chief Scientific Officer at Biombank, a clinical stage biotechnology company with a mission to treat and prevent disease by restoring gut microbial ecology. Dr. Forster’s research focuses on gaining an understanding of the microbial communities that live in our bodies, bringing together experts in microbiology, immunology, and computational biology.
​
Dr. Forster’s team has developed a new way of taking gut samples and looking at the bacteria within normal and damaged gut tissue. Importantly, they have discovered and are testing promising bacteria that could be used to treat, or even cure, IBD. Additionally, Dr Forster aims to identify when bacteria represent a risk and should be removed, and when they could be beneficial and should be added to induce a positive immune response. He has published seminal papers in Nature and Nature Biotechnology detailing culturing of “unculturable” organisms.
DR. EDWARD GILES
HUDSON INSTITUTE - MELBOURNE, AUSTRALIA​
Dr. Edward Giles is an expert in the mucosal immunology of inflammatory bowel diseases, particularly the role of type I interferons and their influence on the adaptive immune system and microbiome of the intestine. He is a Senior Research Scientist in the Regulation of Interferon and Innate Signaling Research Group at the Hudson Institute’s Centre of Innate Immunity and Infectious Diseases. He is also a Fellow of the Royal Australasian College of Physicians and was awarded his PhD on Type I Interferon Signaling in Human Intestinal T Cells from the University of London in 2015. Dr. Giles is also a Consultant Pediatric Gastroenterologist at the Monash Children’s Hospital of the Monash Health Network, where he is lead for pediatric IBD.
DR. RYAN BALFOUR SARTOR
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
​
Dr. Ryan Balfour Sartor is a board-certified gastroenterologist with expertise in managing difficult-to-treat patients with inflammatory bowel diseases (IBD) and a mucosal immunologist/microbiologist with a long-term interest in understanding mechanisms by which resident microbiota induce chronic intestinal inflammation vs. mucosal homeostasis. His research develops and studies rodent models of chronic, immune-mediated intestinal inflammation relevant to IBD and performs clinically relevant translational studies involving IBD patients.
He has explored the functional consequences of microbial communities in selectively colonized gnotobiotic mice and following fecal transplants using murine or human donors. In addition, he investigates host genetically-determined immune responses to luminal resident microbial components using gnotobiotic mice and patient-derived samples, and studies the influence of environmental factors on intestinal microbiota composition and function.
The effect of diet on bacterial metabolic function/bacterial interaction are recent areas of interest. Parallel translational studies in IBD patients explore microbial biomarkers that identify risk of recurrence after Crohn’s disease surgery and onset of pouchitis after colectomy for ulcerative colitis.
DR. KATE JEFFREY
HARVARD MEDICAL SCHOOL, BOSTON
​
Dr. Kate Jeffrey is Executive Director of Immunology and Epigenetices at Moderna and has recently taken a leave of absence from several other positions. These include Associate Professor of Medicine at Harvard Medical School, Principal Investigator in Immunology at Massachusetts General Hospital,Faculty of Harvard immunology and Virology, and Associate member of the Broad Institute of MIT and Harvard.
Dr. Jeffrey’s research focuses on the epigenomic regulation of innate immunity in health and disease. Her work established inhibitors of epigenetic enzymes as anti-inflammatory agents and she recently was the first to describe a loss of an epigenetic enzyme called SP 140 in patients with IBD, as well as with MS. More recently, Dr. Jeffrey has turned her focus on the virome, e.g., viruses that live in the gut, seeking to understand how our intestinal virome influences host innate immunity.
This is an area of study that has, up until recently, not garnered the same attention as gut bacteria, but appears to play a central role in Crohn’s disease. With her findings, Dr. Jeffrey hopes to create personalized, virome-focused therapies that may reduce, reverse or prevent Inflammatory Bowel Disease development through targeted elimination or replacement of disease or health-driving intestinal viruses.
​
Her findings are very exciting and hold enormous promise!
DR. MARCEL BEHR
McGILL UNIVERSITY, MONTREAL, CANADA
Dr. Marcel Behr is an elected fellow at the American Academy of Microbiology, a physician/scientist and also a full professor at McGill University in the Department of Medicine, as well as an associate member in the departments of Epidemiology, Biostatistics, Microbiology, and Immunology. He is the founding director of the McGill University’s International TB Centre and was recently named director of McGill’s Interdisciplinary Initiative in Infection and Immunity.
Dr. Behr’s research focuses on both Mycobacterium Tuberculosis (TB) and Mycobacterium Avium, studying the tuberculosis bacterial genome and the genomic composition of Mycobacterium Avium to understand their pathogenesis (how it causes infection and how infection progresses to disease) and epidemiology of disease (how it spreads among people), and developing better diagnostic tools. In addition, he is studying the role of host pattern recognition receptors, especially NOD2 during infection. He believes that Crohn’s disease shares many similarities with other mycobacteria and sees an association with certain genetic mutations, such as NOD2 that are implicated in both Crohn’s disease and mycobacterial infections.
Research Goal: Dr. Marcel Behr’s research focuses primarily on mycobacteria and its etiological role in human disease. He believes that mycobacterium avium paratuberculosis, which causes Johne's disease in many animals, may play a role in the etiology of Crohn’s disease.
DR. BRAM VERSTOCKT
UNIVERSITY HOSPITALS, LEUVEN, BELGIUM
Bram Verstockt MD, PhD, is a gastroenterologist, holding positions as a clinician and researcher in both the Department of Gastroenterology and Hepatology and the Department of Chronic Diseases and Metabolism | KU Leuven at the University Hospitals Leuven, Belgium. He is interested in translational research focusing primarily on the development of predictive and prognostic markers for a more personalized medicine in IBD, as well as on unravelling IBD disease heterogeneity and perianal disease through multi-omics approaches. Additionally, Dr. Verstockt does clinical research on monitoring tools (including intestinal ultrasound), real-life IBD data (including therapeutic drug monitoring) and is involved in various international studies. In addition, he serves as a reviewer for multiple reviewers including The Lancet, Nature Reviews Gastroenterology and Hepatology, Gut, Gastroenterology, Lancet Gastroenterology and Hepatology, Annals of Internal Medicine, American Journal of Gastroenterology.
Research Goal: To determine predictive biomarkers in disease evolution, including disease heterogeneity and response to treatments.
DR. KEVIN TRACEY
FEINSTEIN INSTITUTES, NEW YORK
Dr. Kevin Tracey, a neurosurgeon by training and CEO of the Feinstein Institutes in New York, along with his colleagues, discovered the direct inflammatory activity of tumor necrosis factor-alpha (TNF), which eventually led to the development of medicines such as Remicade and Humira.
More recently, Dr. Tracey and his lab have been pioneers in the development of devices utilizing bioelectronic medicine, with a particular focus on the role of the vagus nerve in sending signals to the immune system. This work has huge potential to offer safe, life-changing solutions for those suffering from Crohn’s disease, ulcerative colitis, and other inflammatory and autoimmune diseases.
Research Goal: The team is seeking to more fully understand and continue to develop bioelectronic medicine for use in treating Crohn's disease and other chronic conditions.
​
​
DR. BENOIT CHASSAING
INSERM INSTITUTE, PARIS
Dr. Benoit Chassaing earned his PhD in microbiology at the University of Clermont-Ferrand (France), focusing on the possible role of adherent-invasive E. coli (AIEC) in the etiology of Crohn's disease. He also spent time at Georgia State University prior to his current position leading the Chassaing Lab at INSERM in Paris, which specializes in studying the impact of the environment on our microbiota and has conducted groundbreaking research on the role of food additives in inflammation.
The Chassaing lab has previously reported that emulsifiers, highly used by the food industry, are able to detrimentally alter the intestinal microbiota, characterized by an increased ability to penetrate the normally protective mucus layer and increased pro-inflammatory potential. They demonstrated that consumption of emulsifying agents is sufficient to induce intestinal inflammation that will manifest as chronic colitis in genetically susceptible hosts.
Research Goal: Focusing on the mechanisms beyond such observations and understanding how dietary emulsifiers can directly impact the intestinal microbiota and characterize its members which are driving inflammation.
​
​DR. MARK SUNDRUD
​DARTMOUTH COLLEGE
​
Dr. Mark Sundrud was recently appointed a Principal Investigator, at Dartmouth-Hitchcock Medical Center as well as Professor, in the Departments of Medicine, Microbiology & Immunology, Geisel School of Medicine at Dartmouth College, in Hanover, New Hampshire.
​
Previously, Dr. Sundrud was at the University of Florida’s Scripps Institute of Biomedical Research. While there, his team found that certain immune cells in the small intestine have evolved a molecular sensing mechanism to protect themselves from the toxic effects of high bile acid concentrations in the small intestine.
​
Bile acids are made in the liver and released during a meal to help with digestion and absorption of fats and fat-soluble vitamins. Bile is chemically similar to detergent and too much can lead to inflammation and potentially injure the intestinal lining.
​
The research team has discovered that a type of circulating immune system cell called a T helper cell 17, or TH17, can play an important role in digestion. When those circulating cells reach the end part of the small intestine, if they encounter too much bile, they adapt by switching on production of a gene called MDR1. They found that if the MDR1 gene is not present in those circulating immune cells or is mutated in a way that makes it ineffective, bile acids can accumulate in the ilium and injure the intestine.
​
In his latest study, Dr. Sundrud uncovered the mechanism that T-cells use to sense and respond to bile acids in the small intestine to increase MDR1 activity. According to Sundrud, about 10 percent of patients with Crohn’s disease have disease that is driven by bile reabsorption issues, and he is hoping to attract funding to continue this important work.
​
Research Goal: To continue the work validating the behaviors of MDR1 deficient CD4+T cells in Crohn’s disease patients and the therapeutic potential of bile acid sequestrants.
​
​
​DR. BRIAN COOMBES
​​MICHAEL G. DEGROOTE INSTITUTE
​
​​Propel a Cure is pleased and excited to introduce Dr. Brian Coombes, Professor and Chair of Biochemistry & Biomedical Sciences at the esteemed Michael G. DeGroote Institute for Infectious Disease Research (IIDR) at McMaster University. Scientists in Dr. Coombes' lab are conducting basic research to understand the microbes that drive chronic inflammation during Crohn's disease, with a focus on adherent-invasive E. coli.
The innate immune system is a host’s first line of defense against foreign invaders, but pathogens like AIEC use sophisticated strategies to overcome the innate immune system in order to colonize, establish a host niche, and transmit to new hosts. Dr. Coombes' lab has embarked on a line of research to understand the components of the innate immune system involved in protection against enteric pathogens such as Salmonella, pathogenic E. coli, and bacteria associated with Crohn’s disease.
Research Goal: Identifying and understanding microbes driving chronic inflammation leading to Crohn's disease, with a focus on adherent-invasive E. coli and the immune system.
​
​
​​DR. MARK DAVIS
​STANFORD UNIVERSITY
​
​​​Propel a Cure is especially excited to be supporting the eminent immunologist, Dr. Mark Davis and his team in the Davis Lab at Stanford University.
Research Goal: Identification of circulating and tissue-resident CD4+ T cells specific for disease-driving antigens in Crohn’s disease
Propel a Cure has prioritized the funding of a study that would lead to the identification of circulating and tissue-resident CD4+ T cells specific for disease-driving antigens in Crohn’s disease. T cells are a type of white blood cell that appear to have a major role in the body’s overactive inflammatory response that is seen in Crohn’s.
​
​
​​DR. MICHAEL DOLINGER
NYU GROSSMAN SCHOOL OF MEDICINE
​
Dr. Dolinger is the Director of Pediatric Inflammatory Bowel Disease at NYU Langone Health in New York City. His research focuses primarily on the use of intestinal ultrasound as a novel, non-invasive tool to monitor IBD activity and treatment response in order to improve outcomes and enhance shared understanding.
​
​